Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 8—August 2024
Research

Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance

C. Finn McQuaidComments to Author , Theresa S. Ryckman, Nicolas A. Menzies, Richard G. White, Ted Cohen, and Emily A. Kendall
Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (C.F. McQuaid, R.G. White); Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (T.S. Ryckman, E.A. Kendall); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (N.A. Menzies); Yale School of Public Health, New Haven, Connecticut, USA (T. Cohen)

Main Article

Figure 3

Univariate sensitivity analysis for initial TB treatment regimen comparison in study of potential of pan-TB treatment to drive emergence of novel resistance. Parameter sets are sampled with 1 parameter fixed at the extremes of its 95% CI. The outcome is the proportion of samples that result in more patients durably cured in the pan-TB scenario than the SoC scenario, within the first cohort of patients treated, and at current prevalence of resistance. Blue circles indicate use of upper bound of the parameter’s 95% CI; red circles indicate the lower bound. B, diarylquinolines; BX, diarylquinoline- and novel drug X–containing regimen; CFR, case-fatality ratio; DST, drug-susceptibility testing; R, rifamycins; re-treat, patients with previously treated TB; SoC, standard of care; X, additional novel drug X.

Figure 3. Univariate sensitivity analysis for initial TB treatment regimen comparison in study of potential of pan-TB treatment to drive emergence of novel resistance. Parameter sets are sampled with 1 parameter fixed at the extremes of its 95% CI. The outcome is the proportion of samples that result in more patients durably cured in the pan-TB scenario than the SoC scenario, within the first cohort of patients treated, and at current prevalence of resistance. Blue circles indicate use of upper bound of the parameter’s 95% CI; red circles indicate the lower bound. B, diarylquinolines; BX, diarylquinoline- and novel drug X–containing regimen; CFR, case-fatality ratio; DST, drug-susceptibility testing; R, rifamycins; re-treat, patients with previously treated TB; SoC, standard of care; X, additional novel drug X.

Main Article

Page created: June 21, 2024
Page updated: July 20, 2024
Page reviewed: July 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external